WaveMan · Company
BIXT · Bioxytran, Inc
> Search tickers & screens ⌘K
LIVE
← All companies

BIXT Bioxytran (BIXT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001445815
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$177.8K
four quarters, 2017-07-01 to 2018-06-30
History
FY Dec 2025$177.8K
FY Dec 2024$177.8K
FY Dec 2023$177.8K
FY Dec 2022$177.8K
FY Dec 2021$177.8K
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-18.19x
TTM operating cash flow over current debt only, 2025-06-30 (12 months older than the period end)
History
FY Dec 2025-10.95x
FY Dec 2024-7.94x
FY Dec 2023-1.84x
FY Dec 2022-4.29x
FY Dec 2021-4.03x
Jun 2026-18.19x
Mar 2026-12.43x
Dec 2025-10.95x
Sep 2025-8.68x
Jun 2025-9.19x
Mar 2025-9.15x
Dec 2024-7.94x
Sep 2024-0.82x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1,453%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-532.6%
FY Dec 2024-1,702%
FY Dec 2023-1,753%
FY Dec 2022-1,009%
FY Dec 2021-1,809%
Jun 2026-1,453%
Mar 2026-755.6%
Dec 2025-532.6%
Sep 2025-1,493%
Jun 2025-1,784%
Mar 2025-2,416%
Dec 2024-1,702%
Sep 2024-1,587%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.7M
market value at close 2026-10-09 on 2026-08-14 shares, plus current debt only, 2025-06-30 (12 months older than the period end), minus cash 2017-09-30
History
FY Dec 2025$7.5M
FY Dec 2024$7.7M
FY Dec 2023$22.1M
FY Dec 2022$59.4M
FY Dec 2021$44.3M
Jun 2026$3.0M
Mar 2026$4.5M
Dec 2025$7.5M
Sep 2025$6.3M
Jun 2025$9.4M
Mar 2025$12.5M
Dec 2024$7.7M
Sep 2024$20.0M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

BIXT Stock Sonar score 2/7 axes

Find similar shapesCompare
Financial health
19
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-18.19x · 19 pct, sector of 371
Risk and compliance
100
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 814
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Growth, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BIXT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-65.7%12M
-70%-35%-0%+35%2025-102025-122026-022026-042026-062026-082026-10 2025-11-18 · Hoberman Alan M bought $126.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

Bioxytran insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BIOXYTRAN, INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
Hoberman Alan M
Director
BUY
2025-11-18
210,000
$126.0K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 210,000 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director Hoberman Alan M bought about $126.0K of BIXT on the open market on Nov 18, 2025, the largest insider purchase at the company since 2024.
PLATT DAVID
CEO
BUY
2024-08-15
1,592,921
$191.2K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 7.3% of the 21,675,939 shares held after it.
  • No other insider bought within 30 days.
Insider activity: CEO PLATT DAVID bought about $191.2K of BIXT on the open market on Aug 15, 2024, the largest insider purchase at the company on our record.
2 transactions on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns BIXT: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in BIXT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BIXT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income$-1.8M$-2.2M$-3.8M$-2.4M
Net income$-2.1M$-2.4M$-4.5M$-2.5M
EPS (diluted)-0.02-0.02-0.03-0.02
Operating cash flow$-526.5K$-381.3K$-775.4K$-1.8M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies